Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level (Q44827691)

6 December 2017

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level (English)

1 reference

6 December 2017

1 reference

1 reference

1 reference

3

1 reference

6 December 2017

Fang SH

1

1 reference

6 December 2017

Hwang LH

series ordinal

2

1 reference

6 December 2017

Chiang BL

series ordinal

4

1 reference

6 December 2017

1 November 2000

1 reference

6 December 2017

Journal of Hepatology

1 reference

6 December 2017

33

1 reference

6 December 2017

791-798

1 reference

6 December 2017

5

1 reference

Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Lassa fever. Effective therapy with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Antiviral efficacy and toxicity of ribavirin and foscarnet each given alone or in combination in the murine AIDS model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Selective inhibition of functional lymphocyte subpopulations by ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: different antigenic determinants from human B cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Improved gene expression by a modified bicistronic retroviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

A safe packaging line for gene transfer: separating viral genes on two different plasmids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Inhibition of immune functions by antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Production of interleukin-12 by murine macrophages in response to bacterial peptidoglycan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

Interleukin-12 restores dendritic cell function and cell-mediated immunity in retrovirus-infected mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980312-8

7 January 2021

10.1016/S0168-8278(00)80312-8

Identifiers

DOI

1 reference

release_a6l24bzm2jgufm5qqk7m4uwm7m

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a6l24bzm2jgufm5qqk7m4uwm7m

24 November 2022

mapped directly with Wikidata item

1 reference